Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.
Antoine Adenis et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls
Sola Adeleke et al.
PERSONALIZED MEDICINE (2022)
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Leah H. Biller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review
Su Min Cho et al.
FRONTIERS IN PHARMACOLOGY (2021)
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Natalia Kunst et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Molecular Profiling in Metastatic Colorectal Cancer
Benjamin Weinberg et al.
ONCOLOGY-NEW YORK (2020)
Comprehensive review of targeted therapy for colorectal cancer
Yuan-Hong Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem et al.
ONCOLOGIST (2019)
Oncologic Outcomes in Metastatic colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting
Cheng-Jen Ma et al.
TRANSLATIONAL ONCOLOGY (2019)
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
Flavia Fondevila et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Stergios Boussios et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
D. Arnold et al.
ANNALS OF ONCOLOGY (2018)
Multicenter, Randomized, Double-Blind Phase 2 Trial of FOLFIRI With Regorafenib or Placebo as Second-Line Therapy for Metastatic Colorectal Cancer
Hanna K. Sanoff et al.
CANCER (2018)
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer
Julia Sanchez-Gundin et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2018)
Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
Chun-Yu Lin et al.
PLOS ONE (2018)
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2017)
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies
A. Vogel et al.
CANCER TREATMENT REVIEWS (2017)
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy
Eric I. Marks et al.
CANCER BIOLOGY & THERAPY (2015)
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
Guillem Argiles et al.
EUROPEAN JOURNAL OF CANCER (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan plus /- targeted therapy
Dorte Lisbet Nielsen et al.
CANCER TREATMENT REVIEWS (2014)
FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
Chien-Yu Lu et al.
ONCOTARGETS AND THERAPY (2014)
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Share Paper
